iCAD, Inc. (NASDAQ:ICAD) Short Interest Update

iCAD, Inc. (NASDAQ:ICAD - Get Free Report) was the recipient of a large growth in short interest in March. As of March 31st, there was short interest totalling 269,400 shares, a growth of 20.1% from the March 15th total of 224,300 shares. Approximately 1.0% of the company's stock are short sold. Based on an average daily volume of 459,200 shares, the days-to-cover ratio is currently 0.6 days.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in ICAD. Granahan Investment Management LLC purchased a new position in shares of iCAD during the 4th quarter valued at about $96,000. Integrated Wealth Concepts LLC purchased a new position in iCAD during the fourth quarter valued at approximately $92,000. Wells Fargo & Company MN lifted its holdings in iCAD by 51.3% in the fourth quarter. Wells Fargo & Company MN now owns 39,542 shares of the technology company's stock valued at $72,000 after acquiring an additional 13,402 shares during the period. Perritt Capital Management Inc boosted its position in iCAD by 1.9% in the 4th quarter. Perritt Capital Management Inc now owns 189,100 shares of the technology company's stock worth $346,000 after purchasing an additional 3,600 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of iCAD by 6.6% during the 4th quarter. Geode Capital Management LLC now owns 276,493 shares of the technology company's stock worth $506,000 after purchasing an additional 17,059 shares during the period. Hedge funds and other institutional investors own 24.61% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on ICAD. BTIG Research lowered iCAD from a "buy" rating to a "neutral" rating in a research report on Wednesday, April 16th. Craig Hallum lowered shares of iCAD from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, April 16th. StockNews.com cut shares of iCAD from a "hold" rating to a "sell" rating in a research note on Thursday, April 17th. Finally, Laidlaw restated a "hold" rating on shares of iCAD in a research note on Thursday, April 17th.

iCAD Price Performance

ICAD traded down $0.00 on Friday, reaching $3.30. 112,590 shares of the stock were exchanged, compared to its average volume of 370,124. The company's 50-day moving average price is $2.33 and its 200 day moving average price is $2.18. The firm has a market capitalization of $90.20 million, a PE ratio of -25.42 and a beta of 1.78. iCAD has a fifty-two week low of $1.18 and a fifty-two week high of $3.78.

iCAD (NASDAQ:ICAD - Get Free Report) last released its earnings results on Wednesday, March 19th. The technology company reported ($0.03) EPS for the quarter, topping analysts' consensus estimates of ($0.05) by $0.02. iCAD had a negative return on equity of 15.65% and a negative net margin of 17.81%. The firm had revenue of $5.41 million during the quarter, compared to the consensus estimate of $4.72 million.

About iCAD

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.